• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.710 +0.100 (+1.31%)
Streaming Delayed Price Updated: 10:07 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 Next >
News headline image
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conference
November 24, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
November 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
November 04, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
October 28, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
October 24, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program
October 22, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
MissionIRNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI
September 19, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
September 15, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 26, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
August 11, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
July 24, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
July 23, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
June 30, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
June 23, 2025
From Arcturus Therapeutics
Via Business Wire
News headline image
Arcturus Therapeutics to Attend Upcoming Investor Conferences
May 29, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress
May 12, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
April 22, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1
April 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
March 06, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
March 05, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025
February 24, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
February 14, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
February 04, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
January 31, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
January 10, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 06, 2025
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap